Biopharmaceutical company Pharming Group has reduced its full-year 2026 revenue guidance by $30 million, setting a new target range of $375 million to $395 million.
The adjustment followed the release of its second-quarter financial report on July 30, 2026.
>>> UK Investigates British Airways Flight Stall Over London
Despite the downward revision, management highlighted positive patient intake trends during the second quarter as a basis for revenue recovery in the second half of the year.
CEO Fabrice Chouraqui stated that a renewed inflow of new patients supports expectations for Ruconest revenue to stabilize and grow again.
Cost Reductions and Q2 Performance
Alongside the lowered revenue outlook, Pharming reduced its projected annual operating expenses by $15 million.
The new operating cost range is set between $315 million and $320 million, representing a 1% to 3% increase compared to 2025.
Total revenue for the second quarter fell 3% year-over-year to $90.2 million.
>>> Suspected Russian Missile Crashes Deep Inside Polish Territory
Ruconest sales dropped 10% to $72.3 million, though they grew 24% sequentially from the first quarter.
Joenja revenue surged 40% year-over-year to $17.9 million, driven by strong US and international expansion, including its first commercial European launch in Germany after the quarter ended.
Operating profit for the second quarter was $1.3 million, down from $10.8 million in the same period last year.
The decline was attributed to lower overall revenue, inventory write-downs, and costs related to closing its facility in France.
Net profit for the quarter was $1.6 million, bringing the first-half net loss to $3.6 million, a significant improvement from the $10.3 million net loss in the first half of 2025.
>>> US Bitcoin ETFs End Outflow Streak With $32M Inflows as Fed Holds Rates
Looking ahead, Pharming plans to report clinical trial data for leniolisib in larger populations of patients with Common Variable Immunodeficiency (CVID) during the fourth quarter of 2026.
